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METHODS OF ADMINISTERING IGGl
ANTIBODIES AND METHODS OF
SUPPRESSING ANGIOGENESIS

A commonly-used anti-angiogenic drug is bevacizumab,
a humanized IgG 1 monoclonal antibody that targets vascular
endothelial growth factor-A (VEGFA, a.k.a. VEGF) and is
approved for various cancers and widely used in age-related
macular degeneration. Bevacizumab had been thought to
inhibit angiogenesis by targeting human VEGFA; however,
it was reported to inhibit angiogenesis in mouse models 8 - 14 ,
even though bevacizumab does not target mouse VEGFA
and is specific for human VEGFA.
The present inventor surprisingly discovered that bevacizumab acts to suppress angiogenesis not only via its target,
VEGFA, but rather also via activation of Fey RI via its Fe
fragment (FcyRI is also known as CD64). The present
inventor surprisingly discovered that bevacizumab's antiangiogenic activity occurs not only because it is designed to
target a particular protein, but also because it includes an Fe
fragment that is capable of activating Fey RI.
In this regard, as disclosed herein, any IgG 1 antibody
including an Fe fragment, intravenous human immunoglobulin (IVIG), and/or isolated Fe fragment can be used to
suppress angiogenesis.
Several monoclonal antibody therapies are now approved
by the FDA, EMEA, and other regulatory agencies for the
treatment of numerous diseases including age-related macular degeneration (AMD), asthma, autoimmune disorders,
and various cancers 1 . In addition, there are hundreds of
monoclonal antibodies under evaluation in thousands of
clinical trials. Such antibodies that were not contemplated
for use to suppress angiogenesis are proposed herein for a
unique use, with the benefit that many of such antibodies
have already obtained regulatory approval and/or are undergoing clinical safety assessment.
The presently-disclosed subject matter includes methods
of suppressing angiogenesis, which involve administering to
a subject in need of suppression of angiogenesis an isolated
Fe fragment of an IgG 1 antibody, an IgG 1 antibody, and/or
WIG.
In some instances, IgG 1 antibodies can be administered to
treat a subject wherein suppression of angiogenesis is contraindicated (including wherein suppression of angiogenesis
is not desired). In this regard, the presently-disclosed subject
matter also provides for methods of administering IgG
antibodies if suppression of angiogenesis in the subject is
not contraindicated.
The present inventor has also surprisingly discovered that
intravitreous administration of Fe fragment-containing IVIG
suppressed choroidal neovascularization as effectively as
intravenous administration. Accordingly, the presently-disclosed subject matter further includes methods of suppressing angiogenesis, including intravitreously administering to
the subject an isolated Fe fragment of an IgG 1 antibody, an
IgGl antibody, and/or IVIG. Screening methods for identifying angiogenesis suppressors are also provided herein.

RELATED APPLICATION

5

This application claims priority from U.S. Provisional
Patent Application Ser. No. 61/780,105, which was filed on
Mar. 13, 2013, the entire disclosure of which is incorporated
herein by this reference.

10

TECHNICAL FIELD
The presently-disclosed subject matter relates to administration of IgG 1 antibodies, and to suppression of angiogenesis using intravenous human immunoglobulin (IVIG),
IgGl antibodies, and/or Fe fragments of same.

15

INTRODUCTION
20

Angiogenesis is a process of forming new capillaries as
endothelial cells of preexisting blood vessels decompose
extracellular matrix, migrate, divide, and differentiate to
form new capillaries, which does not occur except in a
particular case, such as growth, reproduction, or healing
wounds. However, excessive angiogenesis has been reported
in diseases such as growth and metastasis of a malignant
tumor, age-related macular degeneration, rheumatoid arthritis, diabetic retinopathy, psoriasis, and chronic inflammation.
Formation of blood vessels requires a complicate set of
processes including growth, migration, and division of vascular endothelial cells, and formation of capillaries, and
many vascular endothelial growth factors and vascular
endothelial inhibition factors involved in the set of processes
have been discovered. The vascular endothelial inhibition
factors are activated against activity of the vascular endothelial growth factors, which are necessary in the formation of
blood vessel. Therefore, many anti-angiogenesis products
target vascular endothelial growth factor-A (VEGFA, a.k.a.
VEGF). Fewer products act to suppress angiogenesis via
other targets.
Aberrant angiogenesis is implicated in a variety of diseases that collectively affect nearly 10% of the world's
population. Accordingly, there remains a need in the art for
unique angiogenesis suppressors and new approaches for
suppressing angiogenesis to facilitate the treatment of such
diseases.
SUMMARY
The presently-disclosed subject matter meets some or all
of the above-identified needs, as will become evident to
those of ordinary skill in the art after a study of information
provided in this document.
This Summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
Summary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this Summary or not. To avoid
excessive repetition, this Summary does not list or suggest
all possible combinations of such features.
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BRIEF DESCRIPTION OF THE DRAWINGS
The novel features of the invention are set forth with
particularity in the appended claims. A better understanding
of the features and advantages of the present invention will
be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the
principles of the invention are used, and the accompanying
drawings of which:
FIG. 1: Avastin does not inhibit mouse VEGF signaling.
Western blotting shows that mouse VEGF (mVegf) and
human VEGF (hVegf) induce phosphorylation ofVEGFR2
(pVegfr2) in mouse Py4 endothelial cells. A neutralizing

US 10,562,974 B2
3

4

anti-mouse Vegf antibody reduced mouse VEGF induced
VEGF2 phosphorylation but Avastin (a humanized IgGl
antibody that specifically targets human Vegfbut not mouse
Vegf) did not do so. Avastin did reduce human VEGF
induced VEGFR2 phosphorylation. Tubulin blotting shows
protein loading.
FIG. 2: Lucentis does not inhibit corneal neovascularization. Avastin (a full length humanized IgGl antibody that
specifically targets human VEGF-A but not mouse Vegfa;
red), but not Lucentis (a humanized IgGl Fab antibody
fragment that specifically targets human VEGF-A but not
mouse Vegfa; gray), reduced corneal hemangiogenesis compared to PBS (black) injection in wild-type mice. * P<0.05.
FIG. 3: Avastin and human IgGl inhibit mouse corneal
neovascularization. Intrastromal injection of Avastin
reduced corneal hemangiogenesis compared to PBS injection in wild-type mice. Human IgGl (higG) from R&D
Systems also reduced corneal hemangiogenesis compared to
PBS. * P<0.05.
FIG. 4: Fe fragment of human IgGl inhibits corneal
neovascularization. The Fe fragment of human IgGl
reduced corneal hemangiogenesis compared to PBS injection in wild-type mice.
FIG. 5: Fe fragment of Avastin inhibits corneal neovascularization. An enzymatically cleaved Fe fragment of Avastin (red) reduced corneal hemangiogenesis compared to PBS
(black) injection in wild-type mice.
FIG. 6: Fab fragment of Avastin does not inhibit corneal
neovascularization. An enzymatically cleaved Fab fragment
of Avastin did not reduce corneal hemangiogenesis compared to PBS injection in wild-type mice.
FIG. 7: Deglycosylated Avastin does not inhibit corneal
neovascularization. A deglycosylated form of Avastin,
which does not bind Fey RI, did not reduce corneal hemangiogenesis compared to PBS injection in wild-type mice.
NS, not significant.
FIG. 8: Avastin does not inhibit corneal neovascularization in Fcgrl -/- mice. Avastin did not reduce corneal hemangiogenesis compared to PBS injection in Fcgr1-1- mice.
FIG. 9: Avastin and human IgGl inhibit choroidal neovascularization. Intravitreous injection of Bevacizumab
(Avastin) or human IgGl reduced laser-induced choroidal
neovascularization in wild-type mice compared to PBS. *
P<0.05 compared to PBS.
FIG. 10: Lucentis does not inhibit choroidal neovascularization. Intravitreous injection of Ranibizumab (Lucentis)
did not reduce laser-induced choroidal neovascularization in
wild-type mice compared to PBS. No significant difference.
FIG. 11: Intravitreous injection of Avastin or human IgG 1
did not reduce laser-induced choroidal neovascularization in
Fcgr1-1- mice compared to PBS. No significant difference.
FIG. 12: Coadministration of a peptide inhibitor of IgG
binding to FcyRI (PAM), compared to a control peptide
(CP), blocked the inhibition oflaser-induced choroidal neovascularization by Avastin in wild-type mice.
FIG. 13: (A) Color laser doppler studies were performed
at 2 and 7 days after femoral artery ligation (NI, nonischemic; I, ischemic). The blue areas denote low flow/ischemic
regions, whereas red denotes normal perfusion. Representative images show that whereas animals treated with intramuscular PBS demonstrate substantial reperfusion of the
limb at 7 days, those treated with Avastin or human IgG
injections did not.
FIG. 14: Intramuscular administration of Avastin and
human IgG but not Lucentis in wild-type mice reduced
blood capillary density, expressed as % vascularized area
normalized to myocyte numbers, compared to PBS.

FIG. 15: Coadministration of a peptide inhibitor of IgG
binding to FcyRI (PAM), compared to a control peptide
(CP), blocked the inhibition of hind limb ischemia-induced
neovascularization by Avastin in wild-type mice.
FIG. 16: Campath inhibits corneal neovascularization.
Intrastromal injection ofCampath (a humanized IgGl antibody that specifically targets human CD52 but not mouse
CD52; red) reduced corneal hemangiogenesis compared to
PBS (black) injection in wild-type mice.
FIG. 17: Humira inhibits corneal neovascularization.
Intrastromal injection of Humira (a humanized IgGl antibody that specifically targets human TNF-a but not mouse
TNF-a) reduced corneal hemangiogenesis compared to PBS
injection in wild-type mice.
FIG. 18: Actemra inhibits corneal neovascularization.
Intrastromal injection of Actemra (a humanized IgGl antibody that specifically targets human IL-6R but not mouse
IL-6R) reduced corneal hemangiogenesis compared to PBS
injection in wild-type mice. * P<0.05.
FIG. 19: Arzerra and Synagis inhibit corneal neovascularization. Intrastromal injection of Arzerra (a humanized
IgG 1 antibody that specifically targets human CD20 but not
mouse CD20) or of Synagis (a humanized IgGl antibody
that specifically targets the F protein of respiratory syncytial
virus) reduced corneal hemangiogenesis compared to PBS
injection in wild-type mice. * P<0.05.
FIG. 20: Xolair inhibits corneal neovascularization.
Intrastromal injection ofXolair (a humanized IgG 1 antibody
that specifically targets human IgE but not mouse IgE)
reduced corneal hemangiogenesis compared to PBS injection in wild-type mice. * P<0.05.
FIG. 21: Arzerra inhibits choroidal neovascularization.
Intravitreous injection of atumumab (Arzerra) reduced laserinduced choroidal neovascularization in wild-type mice
compared to PBS. * P<0.05 compared to PBS.
FIG. 22: Synagis inhibits choroidal neovascularization.
Intravitreous injection of palivizumab (Synagis), an antirespiratory syncitial virus protein F IgG 1 antibody that does
not target any mouse protein, reduced laser-induced choroidal neovascularization in wild-type mice compared to
PBS. * P<0.05 compared to PBS.
FIG. 23: Xolair inhibits choroidal neovascularization.
Intravitreous injection of omalizumab (Xolair), an antihuman IgE IgG 1 antibody that does not bind mouse IgE,
reduced laser-induced choroidal neovascularization in wildtype mice compared to PBS. * P<0.05 compared to PBS.
FIG. 24: Actemra inhibits choroidal neovascularization.
Intravitreous injection of tocilizumab (Actemra), an antihuman IL-6R IgG 1 antibody that does not bind mouse
IL-6R, reduced laser-induced choroidal neovascularization
in wild-type mice compared to PBS. * P<0.05 compared to
PBS.
FIG. 25: Campath inhibits choroidal neovascularization.
Intravitreous injection (25 µg) of alemtuzumab (Campath),
an anti-human CD52 IgGl antibody that does not bind
mouse CD52, reduced laser-induced choroidal neovascularization in wild-type mice compared to PBS. * P<0.05
compared to PBS.
FIG. 26: Humira inhibits choroidal neovascularization.
Intravitreous injection (25 µg) of adalimumab (Humira), an
anti-human TNFa IgGl antibody that does not bind mouse
TNFa, reduced laser-induced choroidal neovascularization
in wild-type mice compared to PBS. * P<0.05 compared to
PBS.
FIG. 27: IVIG inhibits corneal neovascularization. Intravenous administration of intravenous human immunoglobu-
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!in (WIG) reduced corneal hemangiogenesis compared to
intravenous PBS (IVPBS) injection in wild-type mice. *
P<0.05.
FIG. 28: IVIG inhibits choroidal neovascularization.
Intravenous administration of intravenous human immunoglobulin (Ivig) reduced the volume of laser-induced choroidal neovascularization in wild-type mice.
FIG. 29: IVIG inhibits hind limb neovascularization.
Intravenous administration of intravenous human immunoglobulin (Ivig) reduced hind limb-induced neovascularization in wild-type mice.
FIG. 30: Local IVIG inhibits choroidal neovascularization. Intravitreous injection of human "intravenous" immunoglobulin reduced laser-induced choroidal neovascularization in wild-type mice compared to PBS. * P<0.05 compared
to PBS.
FIG. 31: Avastin inhibits corneal neovascularization in
humanized FcyR mice. Intravenous administration of intravenous human immunoglobulin (IVIG) reduced corneal
hemangiogenesis compared to intravenous PBS (IVPBS)
injection in humanized FcyR mice compared to PBS. *
P<0.05 compared to PBS.
FIG. 32: Avastin inhibits choroidal neovascularization in
humanized FcyR mice. Intravitreous injection of Avastin
reduced laser-induced choroidal neovascularization in
humanized FcyR mice compared to PBS. * P<0.05 compared to PBS.
FIG. 33: FcyRl expression on resident cells is not
required for Avastin to inhibit corneal neovascularization.
Avastin reduced corneal hemangiogenesis compared to PBS
injection in Fcgrl -/- mice that had been irradiated and had
their bone marrow reconstituted with wild-type mouse bone
marrow. * P<0.05.
FIG. 34: FcyRl expression on circulating cells is required
for Avastin to inhibit corneal neovascularization. Avastin did
not reduce corneal hemangiogenesis compared to PBS injection in wild-type mice that had been irradiated and had their
bone marrow reconstituted with Fcgrl -/- mouse bone marrow. No significant difference.
FIG. 35: FcyRl expression on circulating cells, but not on
resident cells, is required for Avastin to inhibit choroidal
neovascularization. Intravitreous administration of Avastin
reduced laser-induced choroidal neovascularization compared to PBS injection in Fcgr1-1- mice that had been
irradiated and had their bone marrow reconstituted with
wild-type mouse bone marrow. Avastin did not reduce
laser-induced choroidal neovascularization compared to
PBS injection in wild-type mice that had been irradiated and
had their bone marrow reconstituted with Fcgrl -/- mouse
bone marrow.
FIG. 36: Avastin and IgG inhibit mouse Vegfa-induced
migration of wild-type (wt) mouse bone marrow derived
macrophages across a Transwell filter.
FIG. 37: Avastin and IgG do not inhibit mouse Vegfainduced migration of Fcgrl knockout (ko) mouse bone
marrow derived macrophages across a Transwell filter.
FIG. 38: Avastin and IgG do not inhibit mouse Vegfainduced migration of c-cbl knockout (ko) mouse bone
marrow derived macrophages across a Transwell filter.
FIG. 39: Stimulation with Avastin (100 µg/ml) induced
phosphorylation of c-cbl (p-c-cbl) in wild-type mouse bone
marrow derived macrophages over a 20-minute period compared to no treatment (NoTx), as monitored by western
blotting.

FIG. 40: c-cbl is required for Avastin to inhibit corneal
neovascularization. Avastin did not reduce corneal hemangiogenesis compared to PBS injection in c-cb1-1- mice. No
significant difference.
5

DESCRIPTION OF EXEMPLARY
EMBODIMENTS

10

15

20

25

30

35

40

45

50

55

60

65

The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
The presently-disclosed subject matter includes methods
of administering an IVIG containing an Fe fragment, an
IgG 1 antibody contacting an Fe fragment, and/or an isolated
Fe fragment. The presently-disclosed subject matter further
includes methods of suppressing angiogenesis. The presently-disclosed subject matter further includes methods of
screening for angiogenesis suppressors.
With regard to the use of an isolated Fe fragment, it is
noted that Fcgrl has not been previously associated with
suppression of angiogenesis in any published report. Moreover, since both Lucentis (an IgGl Fab fragment) and
Avastin (a full-length IgGl containing both the Fab and Fe
fragments) suppress angiogenesis, one of ordinary skill in
the art would have surmised that the Fe fragment is unnecessary for anti-angiogenic activity. As such, it is unexpected
that the isolated Fe fragment has utility for anti-angiogenic
treatment.
Unless otherwise indicated, the term "administering" is
inclusive of all means known to those of ordinary skill in the
art for providing a pharmaceutical preparation to a subject,
administration by inhalation, nasal administration, topical
administration, intravaginal administration, ophthalmic
administration, intraaural administration, intracerebral
administration, intravitreous administration, intracameral
administration, posterior sub-Tenon administration, posterior juxtascleral administration, subretinal administration,
suprachoroidal administration, cell-based administration or
production, rectal administration, and parenteral administration, including injectable such as intravenous administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can
be continuous or intermittent. A preparation can be administered therapeutically; that is, administered to treat an
existing condition of interest. A preparation can be administered prophylactically; that is, administered for prevention
of a condition of interest.
As used herein, the term "contraindicated" refers to any
condition in a patient which renders a particular line of
treatment, including the administration of drugs (e.g., an
anti-angiogenic agent), undesirable or improper. This condition may be preexisting, or may develop while the patient
is taking the drugs, including conditions which may result
directly or indirectly from treatment with the drugs. A
particular line of treatment, including administration of
drugs, may also be considered "contraindicated," as the term
is used herein, if use of a drug by subjects who are also
taking another drug is known or suspected of producing an
adverse side effect in those subjects.
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As used herein, "IgG 1 antibody" or "IgG 1" refer to
immunoglobulin G subclass 1, including an Fe region or Fe
fragment, i.e., the Fe fragment has not been cleaved from the
antibody. Antibodies as used herein include monoclonal,
polyclonal, chimeric, single chain, bispecific, simianized,
human, and humanized or primatized antibodies. As used
herein, "intravenous human immunoglobulin (IVIG)" refers
to the blood product, including IgG, including an Fe region
or Fe fragment, i.e., the Fe fragment has not been cleaved
from the antibody. "Fe region" and "Fe fragment" refer to
the Fragment, crystalizable (Fe) region of an IgG 1 antibody.
The term "isolated" when used in the context of an Fe
fragment, is the Fe fragment that exists apart from the
remainder of an IgGl antibody. Use of the term "isolated"
in connection with an Fe fragment does not preclude that the
Fe fragment may comprise additional amino acids or other
elements that are not particularly part of the Fe region;
rather, it is simply to clarify that the Fe fragment exists apart
from the remainder of the IgG 1 antibody.
As used herein, the term "subject" refers to a target of
treatment. The subject of the herein disclosed methods can
be a vertebrate, such as a mammal, a fish, a bird, a reptile,
or an amphibian. Thus, the subject of the herein disclosed
methods can be a human or nonhuman. Thus, veterinary
therapeutic uses are provided in accordance with the presently disclosed subject matter.
As will be recognized by one of ordinary skill in the art,
the terms "suppression," "suppressing," "suppressor," "inhibition," "inhibiting" or "inhibitor" do not refer to a complete
elimination of angiogenesis in all cases. Rather, the skilled
artisan will understand that the term "suppressing" or
"inhibiting" refers to a reduction or decrease in angiogenesis. Such reduction or decrease can be determined relative
to a control. In some embodiments, the reduction or decrease
relative to a control can be about a 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26,27, 28,29,30, 31, 32,33,34, 35,36,37,38, 39,40,41,
42,43, 44,45,46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73,
74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89,
90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% decrease.
As used herein, the terms "treatment" or "treating" relate
to any treatment of a condition of interest, including but not
limited to prophylactic treatment and therapeutic treatment.
As such, the terms treatment or treating include, but are not
limited to: preventing a condition of interest or the development of a condition of interest; inhibiting the progression
of a condition of interest; arresting or preventing the development of a condition of interest; reducing the severity of a
condition of interest; ameliorating or relieving symptoms
associated with a condition of interest; and causing a regression of the condition of interest or one or more of the
symptoms associated with the condition of interest.
In some embodiments of the presently-disclosed subject
matter the method includes identifying a subject in need of
treatment with an IgG 1 antibody; determining whether suppression of angiogenesis in the subject is contraindicated;
and if suppression of angiogenesis in the subject is not
contraindicated, administering the IgG 1 antibody. In some
embodiments, the IgG 1 antibody is not selected from the
IgG 1 antibodies set forth in Table A. In some embodiments,
the IgG 1 antibody is selected from the IgG 1 antibodies set
forth in Table B.
In some embodiments of the presently-disclosed subject
matter the method includes identifying a subject in need of
suppression of angiogenesis; and administering to the subject an isolated Fe fragment of an IgGl antibody and/or an

IgG 1 antibody. In some embodiments, the IgG 1 antibody is
not selected from the IgG 1 antibodies set forth in Table A.
In some embodiments, the IgG 1 antibody is selected from
the IgGl antibodies set forth in Table B.
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TABLE A
Bevacizumab (Avastin)
Trastuzumab (Herceptin)
10

Ado-trastuzwnab emtansine

Efalizumab (Raptiva)
Canakinumab (Ilaris)
Pertuzumab (Perjeta)

(Kadcyla)
Adalimumab (Humira)
Golimumab (Simponi)

immunoglobulin (!VIG)
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TABLE B
Tocilizumab (Actemra)
Atilizumab (RoActemra)
Ofatumumab (Arzerra)
Alemtuzumab (Campatb)
Palivizumab (Synagis)
Motavizumab (Numax)
Raxibacumab (ABThrax)
Belimumab (Benlysta)
Omalizumab (Xolair)
Ipilmumab (Yervoy)
Daclizumab (Zenapax)
Ustekinumab (Stelara)
Alefacept (Amevive)
Elotuzumab

ACE-011
ACE-031
MGAWNl
NCTOl 736683
MNRP1685A
IMC-A12
IMC 1121B
FG-3019
MT203
Necitumwnab
Immunex

hLLl
IMGN388
AMG479

AIN457
CD4-IgG
J695
BIIB023
AIN457
IMC-1121B
MEDI4893
Nimotuzumab
Mepolizumab
TRC105
solanezwnab

ficlatuzumab

In some embodiments of the presently-disclosed subject
matter the method includes identifying a subject in need of
suppression of angiogenesis; and intravitreously administering to the subject an isolated Fe fragment of an IgGl
antibody, an IgG 1 antibody, and/or intravenous human
immunoglobulin (IVIG).
Neither WIG nor IgGl antibodies (apart fromAvastin) are
formulated for intraocular administration. As such, they are
not contemplated for such a mode of delivery. Furthermore,
the IgG 1 the IgG 1 antibodies in Table B are not known to
influence previously described pathways of angiogenesis. As
such, their use in the eye would not be expected. Nevertheless, the present inventor discovered that Intravitreous
administration is surprisingly effective.
Damianovich et al. reports that WIG reduces angiogenesis
and attributes it to the presence of anti-VEGF antibodies
contained in the IVIG. Therefore, one of ordinary skill in the
art would not expect "generic" IgGs not containing antiVEGF antibodies to suppress angiogenesis. See Damianovich et al. Anti-vascular endothelial growth factor
(VEGF) specific activity of intravenous immunoglobulin
(IVIg). Int. Immunol. (2009) 21 (9): 1057-1063. Surprisingly, as reported herein, such IgGs that do not contain
anti-VEGF antibodies indeed suppress angiogenesis.
The presently-disclosed subject matter includes methods
involving administration of a combination of an isolated Fe
fragment of an IgGl antibody, an IgGl antibody, and/or
IVIG; and a drug that is otherwise useful for in the context
of suppressing angiogenesis. The presently-disclosed subject matter further includes compositions that include an
isolated Fe fragment of an IgG 1 antibody, an IgG 1 antibody,
and/or IVIG; and a drug that is otherwise useful for in the
context of suppressing angiogenesis.
In some embodiments of the methods as described herein,
the method further involves administering a drug selected
from the group consisting of: Avastin, Lucentis, Herceptin,
sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient), everolimus (Afinitor).
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In some embodiments of the presently-disclosed subject
matter, a method of suppressing angiogenesis involves identifying a subject in need of suppression of angiogenesis; and
administering to the subject an isolated Fe fragment of an
IgGl antibody, an IgGl antibody, and/or IVIG; and a drug
selected from the group consisting of: Avastin, Lucentis,
Herceptin, sorafenib (Nexavar), sunitinib (Sutent),
pazopanib (Votrient), everolimus (Afinitor).
In some embodiments of the presently-disclosed subject
matter, a method of suppressing angiogenesis involves identifying a subject in need of suppression of angiogenesis; and
administering to the subject a pharmaceutical composition,
which includes an isolated Fe fragment of an IgG 1 antibody,
an IgG 1 antibody, and/or IVIG; and a drug selected from the
group consisting of: Avastin, Lucentis, Herceptin, sorafenib
(Nexavar), sunitinib (Sutent), pazopanib (Votrient), everolimus (Afinitor).
The presently-disclosed subject matter further includes a
pharmaceutical composition, comprising an isolated Fe fragment of an IgGl antibody, an IgGl antibody, and/or IVIG;
and a drug selected from the group consisting of: Avastin,
Lucentis, Herceptin, sorafenib (Nexavar), sunitinib (Sutent),
pazopanib (Votrient), everolimus (Afinitor).
In some embodiments, the composition can further
include a pharmaceutically acceptable carrier. As used
herein, the term "pharmaceutically acceptable carrier" refers
to sterile aqueous or nonaqueous solutions, dispersions,
suspensions or emulsions, as well as sterile powders for
reconstitution into sterile injectable solutions or dispersions
just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include
water, ethanol, polyols (such as glycerol, propylene glycol,
polyethylene glycol and the like), carboxymethylcellulose
and suitable mixtures thereof, vegetable oils (such as olive
oil) and injectable organic esters such as ethyl oleate. Proper
fluidity can be maintained, for example, by the use of
coating materials such as lecithin, by the maintenance of the
required particle size in the case of dispersions and by the
use of surfactants. These compositions can also contain
adjuvants such as preservatives, wetting agents, emulsifying
agents and dispersing agents. Prevention of the action of
microorganisms can be ensured by the inclusion of various
antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be
desirable to include isotonic agents such as sugars, sodium
chloride and the like. Prolonged absorption of the injectable
pharmaceutical form can be brought about by the inclusion
of agents, such as aluminum monostearate and gelatin,
which delay absorption. Injectable depot forms are made by
forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio
of drug to polymer and the nature of the particular polymer
employed, the rate of drug release can be controlled. Depot
injectable formulations are also prepared by entrapping the
drug in liposomes or microemulsions which are compatible
with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining
filter or by incorporating sterilizing agents in the form of
sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just
prior to use. Suitable inert carriers can include sugars such
as lactose. Desirably, at least 95% by weight of the particles
of the active ingredient have an effective particle size in the
range of 0.01 to 10 micrometers.
In some embodiments of the methods described herein,
the subject in need of treatment for a condition associated

with angiogenesis. Conditions associated with angiogenesis
will be known to those of ordinary skill in the art and
include, but are not limited to cancer, diabetic blindness,
age-related macular degeneration, rheumatoid arthritis, psoriasis, atherosclerosis.
The presently-disclosed subject matter further includes
methods of identifying angiogenesis suppressors, including
measuring activation of FcyRI and/or c-cbl. In some
embodiments, the method of identifying angiogenesis suppressors involves determining the ability of the candidate
suppressor to induce phosphorylation of c-cbl in macrophages, endothelial cells, or other cells, e.g., by Western
blotting. In some embodiments, the method of identifying
angiogenesis suppressors involves determining the ability of
the candidate suppressor to bind with Fey RI, e.g., by ELISA
or surface plasmon resonance assays.
While the terms used herein are believed to be well
understood by one of ordinary skill in the art, definitions are
set forth herein to facilitate explanation of the presentlydisclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
presently-disclosed subject matter belongs. Although any
methods, devices, and materials similar or equivalent to
those described herein can be used in the practice or testing
of the presently-disclosed subject matter, representative
methods, devices, and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and
claims are approximations that can vary depending upon the
desired properties sought to be obtained by the presentlydisclosed subject matter.
As used herein, the term "about," when referring to a
value or to an amount of mass, weight, time, volume,
concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
±10%, in some embodiments ±5%, in some embodiments
±1 %, in some embodiments ±0.5%, and in some embodiments ±0.1 % from the specified amount, as such variations
are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10"
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
The presently-disclosed subject matter is further illustrated by the following specific but non-limiting examples.
The following examples may include compilations of data
that are representative of data gathered at various times
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during the course of development and experimentation
related to the present invention.

control peptide, eliminated the ability of bevacizumab to
inhibit choroidal neovascularization in wild-type mice (FIG.
12).

EXAMPLES

Example 3: Bevacizumab Inhibits Mouse Hind
Limb Angiogenesis Via FcyRI

Example 1: Bevacizumab Inhibits Mouse Corneal
Angiogenesis Via FcyRI
Bevacizumab has no detectable binding to mouse Vegfa
by surface plasmon resonance and does not block mouse
Vegfa-induced retinal capillary endothelial cell proliferation5-7. To further verify that bevacizumab does not functionally neutralize mouse Vegfa, its ability to inhibit the
activation of the Vegfr2 receptor tyrosine kinase in mouse
Py4 hemangioma endothelial cells was tested. As expected,
bevacizumab inhibited Vegfr2 phosphorylation induced by
human VEGFA but not by mouse Vegfa (FIG. 1). In contrast,
an anti-mouse Vegfa neutralizing antibody blocked mouse
Vegfa-induced Vegfr2 phosphorylation.
The effects ofbevacizumab were tested in a mouse model
of suture-injury-induced corneal angiogenesis that is pathophysiologically relevant to the human condition and is
driven in large part by Vegfa 16 . Various drugs were injected
into the cornea stroma immediately after surgery and at 4
and 8 days thereafter. By day 10, it was found that bevacizumab inhibited corneal hemangiogenesis in wild-type mice
compared to PBS administration (FIG. 2). However, administration of equimolar amounts of ranibizumab, a humanized
monoclonal IgGl Fab fragment that binds human VEGFA
but not mouse Vegfa 6 •1 7, did not inhibit corneal hemangiogenesis (FIG. 2). Since bevacizumab and ranibizumab had
nonsynonymous effects in this mouse model, it was suspected that the anti-angiogenic action of bevacizumab was
due not to Vegfa inhibition but rather due to IgGl Femediated effects.
Indeed, purified human IgG 1 as well as recombinant
human IgGl-Fc reduced corneal hemangiogenesis in wildtype mice (FIGS. 3 and 4). The Fab and Fe fragments of
bevacizumab resulting from papain enzymatic digestion
were tested and it was found that bevacizumab-Fc but not
bevacizumab-Fab reduced corneal hemangiogenesis in wildtype mice (FIGS. 5 and 6). Deglycosylation of human IgG 1
dramatically reduces its binding to the high affinity FcyRI
receptor (encoded by Fcgrl) 18 •19 . It was found that deglycosylated bevacizumab did not reduce corneal hemangiogenesis in wild-type mice (FIG. 7). In addition, bevacizumab did not inhibit corneal hemangiogenesis in Fcgr1-1mice (FIG. 8). Collectively, these data indicate that bevacizumab reduces mouse corneal neovascularization via FcyRI
and not Vegfa inhibition.
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Example 4: Numerous Human IgG 1s Inhibit Mouse
Models of Angiogenesis Via Fey RI
Next, several human or humanized IgGl monoclonal
antibodies that are approved for treatment of various human
diseases were tested-adalimumab (Humira™: anti-TNFa),
alemtuzumab (Campath™: anti-CD52), ofatumumab
(Arzerra™: anti-CD20), omalizumab (Xolair™: anti-IgE),
tocilizumab (Actemra™: anti-IL-6R)-and that do not bind
the mouse homologues of their intended human protein
targets, as well as palivizumab (Synagis: anti-respiratory
syncitial virus protein F), which has no mammalian target.
It was found that these antibodies reduced both corneal and
choroidal angiogenesis in wild-type mice (FIG. 16-26).
Collectively, these data indicate that angioinhibition is a
target-independent class effect of human or humanized IgG 1
monoclonal antibodies that is mediated via FcyRI.
Example 5: IVIG Inhibit Mouse Models of
Angiogenesis Via FcyRI

45

50

Example 2: Bevacizumab Inhibits Mouse Choroidal
Angiogenesis Via FcyRI
55

Next, a mouse model of laser injury-induced choroidal
neovascularization was tested, which is a widely used model
of neovascular AMD that is driven in large part by Vegfa and
was predictive of the success of anti-VEGFA therapies in
humans. Various drugs were administered by intravitreous
injection immediately after surgery. By day 7, it was found
that bevacizumab or human IgG 1 but not ranibizumab
inhibited choroidal neovascularization in wild-type mice
compared to PBS administration (FIGS. 9 and 10). However, neither bevacizumab nor human IgG 1 inhibited charoidal neovascularization in Fcgr1-1- mice (FIG. 11). A
peptide that blocks IgG binding to FcyRI (ref. 20 ), but not a

Next, an angiogenesis model outside the eye was tested;
hind limb ischemia was induced by femoral artery ligation,
and drugs were administered intramuscularly at the time of
surgery and 2 days thereafter. Color laser doppler imaging 2
days after ligation revealed significant reduction in blood
flow in the injured limbs of all experimental groups. By day
7, PBS-injected limbs exhibited vascular rescue that was
comparable to the contralateral untreated, nonischemic limb;
however, limbs injected with bevacizumab or human IgGl
exhibited suppressed revascularization and diminished perfusion (FIG. 13). There was a corresponding reduction in
CD31 + capillary density (hemangiogenesis) in the bevacizumab-treated and human IgG I-treated limbs compared
with the PBS-treated group (FIG. 14). The peptide that
blocks IgG binding to FcyRI eliminated the ability of
bevacizumab to inhibit hind limb neovascularization in
wild-type mice (FIG. 15).

60

Human intravenous immunoglobulin (WIG), a purified
IgG fraction obtained from the pooled plasma of thousands
of donors and comprised principally oflgG 1, is approved for
the treatment of numerous primary immunodeficiency 24 . It
is also widely used in an "off-label" fashion to treat a wide
range of dermatological, neurological, inflammatory, and
transplantation-related diseases and widely used to treat
inflammatory diseases. It was found that intravenous administration of IVIG inhibited corneal and choroidal neovascularization in wild-type mice, compared to PBS administration (FIG. 27-29). The degree of angioinhibition was similar
to that exerted by intraocular administration of various
humanized IgG 1 antibodies reported above. Interestingly, it
was found that intravitreous administration of WIG suppressed choroidal neovascularization in wild-type mice as
effectively as intravenous administration of WIG (FIG. 30).
These data open the possibility of intraocular administration
of IVIG as an anti-angiogenic therapy.
Example 6: mAbs Reduce Angiogenesis in FcyR
Humanized Mice
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Although human IgGl binds and activates mouse FcyRI
similarly as it does human Fey RI, the structural diversity and
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unique cellular expression patterns of mouse and human
FcyRs are not synonymous 25 . The generation of an FcyR
humanized mouse via transgenic expression of the entire
human FcyR family, under the control of their human
regulatory elements, on a genetic background lacking all
mouse FcyRs has enabled better prediction of the functional
consequences of engaging human Fey Rs by IgGs (ref. 26 ). In
these FcyR humanized mice, it was found that bevacizumab
reduced corneal and choroidal neovascularization just as in
wild-type mice (FIGS. 31 and 32). These data further
increase the likelihood that similar, target-independent
angioinhibitory activity of humanized monoclonal IgG 1
antibodies or WIG could be observed in humans.

previously. CNV volumes per laser lesion were compared by
hierarchical logistic regression using repeated measures
analysis.
Cornea Suture Placement.
In anesthetized animals, two interrupted 11-0 nylon
sutures (Mani, Inc., Utsunomiya, Japan) were placed into the
corneal stroma, midway between the central corneal apex
and the limbus (approximately 1.25 mm from the limbus), of
both eyes of mice. Delivery of antibodies (100 µg) or PBS
was performed into corneal stroma on day O (immediately
after suture placement), day 4, and day 8 following injection.
Injections were performed using a 33-gauge Exmire
Microsyringe (Ito Corporation) Animals were sacrificed at
day 10, the eyes were enucleated, and the corneas were
dissected for further analyses.
Corneal Flat Mounts.
After euthanasia, the corneas were isolated, washed in
PBS, and fixed in 4% paraformaldehyde for 1 hour and
acetone for 20 minutes at room temperature. Corneas were
washed in 0.1 % Tween-20 in PBS and blocked in 3% BSA
in PBS for 48 hours. Incubation with rabbit anti-mouse
LYVE-1 antibody (1:333; Abeam) and rat anti-mouse CD31
antibody (1:50; BD Biosciences, San Jose, Calif.) was
performed for 48 hours at 4 ° C. The corneas were washed in
0.1 % Tween-20 in PBS and incubated for 2 hours with Alexa
Fluor 488 (goat anti-rabbit; 1:200; Invitrogen) and Alexa
Flour 594 (goat anti-rat; 1:200; Invitrogen). Corneal flat
mounts were visualized under fluorescent microscopy
(Olympus, Tokyo, Japan). The images were adjusted for
brightness/contrast, and converted to black and white
images. Next, whole corneas were outlined using ImageJ
software (NIH). Contours of lymphatic or bloodstained
vessels inside the previously outlined area were optimized
by threshold and converted to binary images. Area fraction
(%) of neovascularized cornea was calculated compared to
whole corneal surface.
Peptide Synthesis.
The tetrameric tripeptide PAM (D-Arg-D-Thr-D-Tyr)4-LLys2-L-Lys-Gly, and the scrambled control peptide (D-ThrD-Tyr-D-Arg)4-L-Lys2-L-Lys-Gly, (MW 2144), were produced by solid-phase peptide synthesis by using amino acids
in the D configuration. Purified peptides were dissolved at
the working concentration in PBS.
Hindlimb Ischemia.
C57Bl/6J mice (N=7 per group) were anesthetized before
underwent unilateral proximal femoral artery ligation. The
right femoral artery was gently isolated, ligated and excised
distal to the deep femoral artery and 0.5 cm proximal to the
bifurcation in saphenous and popliteal arteries, as previously
described (3). The non-ischemic left limb underwent a sham
surgery without arterial ligation Immediately following surgery and after 48 h, Avastin (375 µg), Lucentis (300 µg),
Human IgG (375 µg), PAM peptide (1 mg), Avastin plus
PAM or Avastin plus Control Peptide (1 mg) were intramuscularly administered in a total volume of 30 µL to each
hindlimb. The same volume of PBS was injected in control
group. To evaluate the activity of commercial human intravenous immunoglobulin (IVIG), 0.5 ml (2 g/kg) of IVIG
(Baxter) or PBS were delivered intravenously by tail vein
injection immediately after surgery and after 72 h. 7 days
later, both anterior and posterior muscles from ischemic and
non-ischemic hindlimbs were harvested and processed for
immunohistochemical analysis to quantify angiogenesis and
lymphangiogenesis. In order to evaluate monocyte-macrophage infiltrate, C57Bl/6J mice underwent artery ligation

Example 7: IgGl mAbs Reduce Angiogenesis Via
c-cbl in Macrophages
To determine whether circulating or resident cell types
were the critical effectors in IgGl mAb-mediated angioinhibition, bone marrow chimeric mice were created. Bevacizumab suppressed angiogenesis in the cornea and the
choroid in Fcgrl -/- mice receiving wild-type bone marrow
but did not do so in wild-type mice receiving Fcgrl -I- bone
marrow (FIG. 33-35). These results indicate that FcyRI
expression in circulating bone marrow-derived cells is critical for bevacizumab-induced angioinhibition. The effects of
humanized IgG 1 mAbs on macrophages were studied
because these circulating immune cells play a critical role in
angiogenesis. Both bevacizumab and human IgG 1 inhibited
mouse Vegfa-induced migration of wild-type mouse bone
marrow derived macrophages (BMDMs) but not ofFcgr1-1or c-cbr- 1- BMDMs (FIG. 36-38).
Bevacizumab induced phosphorylation of c-cbl (FIG. 39),
a kinase that is activated by IgGl binding to FcyRI, in
wild-type mouse bone marrow derived macrophages. Bevacizumab did not inhibit corneal neovascularization in
c-cbr- 1- mice (FIG. 40), indicating that c-cbl activation is
essential in this process.
Example 8: Methods
Animals.
All animal experiments were in accordance with the
guidelines of the University of Kentucky Institutional Animal Care and Use Committee, and the Association for
Research in Vision and Ophthalmology (ARVO) Animal
Statement for the Use of Animals in Ophthalmic and Vision
Research. C57B16/J mice were purchased from The Jackson
Laboratory (Bar Harbor, Me.). For all procedures, anesthesia
was performed by intraperitoneal injection of 100 mg/kg
ketamine hydrochloride (Ft. Dodge Animal Health, Ft.
Dodge, Iowa) and 10 mg/kg xylazine (Phoenix Scientific, St.
Joseph, Mo.). Pupils were dilated with topical tropicamide
(1 %; Alcon Laboratories, Inc., Fort Worth, Tex.).
Choroidal N eovascularization.
Subretinal injections of antibodies (25 µg in 1 µL) in mice
were performed using a Pico-Injector (PLI-100; Harvard
Apparatus, Holliston, Mass.). CNV had been induced by
laser photocoagulation (532 nm, 200 mW, 100 ms, 75 µm;
OcuLight GL; IRIDEX Corporation, Mountain View, Calif.)
performed on both eyes (4 spots per eye for volumetric
analyses) of each 6- to 8-week-old male mice (N=4 per
group). Seven days later CNV volumes were measured by
staining with 0.5% FITC-conjugated Griffonia simplicifolia
Isolectin B4 (Vector Laboratories, Burlingame, Calif.).
RPE-choroidal flat mounts using scanning laser confocal
microscope (TCS SP; Leica, Wetzlar, Germany), as reported
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(n=5 per group) and the treatment with IVIG. Muscles were
harvested at day 2, 4 and 7 for immunohistochemical
analysis.
IHC Analyses.
For mouse tissues, capillaries were stained with antiCD31 (BD Biosciences) or anti-LYVE-1 antibodies (Abeam), monocyte-macrophages with anti-F4/80 (Serotec),
and then with biotin labeled Goat anti rat secondary antibodies (Dako ). For human tissues, capillaries were stained
with anti-CD-31 (Dako) or anti-LYVE-1 antibodies (Abcam) and then with biotin labeled goat anti mouse secondary
antibodies (Dako ). Five optical fields for each sample were
analyzed. Capillary number was normalized to myocyte
number. Ischemic/non-ischemic ratio of vessel density or
F4/80 positive area was calculated.
Color Laser Doppler Analysis.
Color laser doppler analysis were performed 2 and 7 days
after femoral artery ligation using a dedicated Laser Doppler
Perfusion Imaging System (LDPI, Petimed AB) with high
resolution, in single mode. Hindlimbs were depilated and
mice were placed on a heating plate at 37° C. The distance
between the seamier head and tissue surface was 8 cm. An
area of 5x5 cm was sequentially scamied and blood flow 1
mm under the surface was measured. Color-coded images
were recorded, and analyses were performed calculating the
average perfusion of the right and left distal limb. Dark blue
color implied low or absent perfusion whereas red implied
maximal perfusion.
Macrophage Migration Assay.
2xl04 BMDM cells were isolated from mice and suspended in 2% BMDM medium and seeded onto the upper
chamber of the 8 µM polycarbonate filter (12-transwell
format. The antibodies namely Avastin or IgG at concentration of 0.1 mg/ml or recombinant mouse Vegfa (50 ng/ml)
were placed in the lower chamber. After 4 h of incubation the
lower chambers with Avastin and IgG were respectively
replaced with Avastin+mouse Vegfa and IgG+mouse Vegfa
and incubated for 12 h. Macrophages that had not migrated
and remained in the upper chamber were removed by gently
washing the upper chamber with PBS and fixed with 4%
buffered paraformaldehyde for 15 min and permeabilized
with 0.025% triton-Xl00 for 10 min followed by staining
with Hoescht (1: 1000) for 30 min. The membrane inserts
were washed and filers inserts were mounted using
Vectashield fluorescence mounting medium. BMDM cells
found on the filter, in the lower chamber, were counted as
cells having undergone chemotaxis and quantified by fluorescence for cell number. Macrophages were quantified for
total number of cells migrated from the entire 32 mm
diameter membrane (20x magnification of montage images)
acquired using Cell Dimension Software. Cell numbers were
acquired using NIH-Image J and the experiment for each
condition was performed in triplicate.
Receptor Phosphorylation and Western Blotting.
Py4 mouse blood endothelial cells were starved for 16
hours in absence of FBS. To induce VEGFR-2 activation,
cells were stimulated with 50 ng/ml of mVegf-A or
hVEGF-A for 10 minutes. 0.1 mg/ml Avastin (Genentech)
was added to medium at the same time. As a control, 0.75
µg/ml neutralizing anti-mouse Vegf-AmAb (R&D Systems)
was used. To activate c-cbl phosphorylation, 1774 mouse
macrophages were starved for 4 h in absence of FBS and
then stimulated with 0.1 mg/ml of Avastin (Genentech) or
human IgG (Sigma-Aldrich) for 45 min. Cells lysed in RIPA
lysis buffer (Sigma-Aldrich) supplemented protease cocktail
inhibitor were homogenized by sonication. Equal amounts
of protein samples (20-40n) prepared in Laemmli buffer

were resolved by SDS-PAGE on Novex® Tris-Glycine Gels
(Invitrogen), and transferred onto Immun-Blot PVDF membranes (Bio-Rad). The transferred membranes were blocked
for 1 hr at RT and incubated with antibodies against phospho-VEGFR2 (1: 1000; Cell Signaling) or phospho-c-Cbl
(1: 1000; Cell Signaling), at 4'C overnight. The immunoreactive bands were developed by enhanced chemiluminescence reaction. Protein loading was assessed by western
blotting using an anti-Tubulin antibody (1:1000; SigmaAldrich).
Avastin Deglycosylation.
To deglycosylate Avastin, it was treated with PNGaseF
(New England BioLab, Beverly, Mass.). Briefly, the Avastin
were first denatured at 100° C. for 10 min in glycoprotein
denaturing buffer and then chilled on ice. Following addition
of G7 reaction buffer, the deglycosylation enzyme cocktail
was added and incubated reaction at 37° C. for 4 hours.
Either mock-treated or deglycosylated Avastin were subjected to SDS-PAGE and Coomassie to appreciate the
mobility shift following the glycosylation procedure.
Avastin Fab/Fc Fragmentation.
Avastin Fe and Fab fragments were prepared by using a
ImmunoPure Fab Preparation Kit (Thermo Fisher Scientific)
according to the manufacturer's instructions. In brief, 4 mg
of Avastin was mixed with 0.5 ml of immobilized papain.
The mixture was incubated by shaking overnight at 37° C.
Crude digest was separated from immobilized papain and
applied to a protein A colunm (Affinity Pak; Thermo Fisher
Scientific). Fab fragments were recovered in the flow
through. Fe fragments and undigested IgG bound to the
colunm were eluted with elution buffer. The fragmentation
was confirmed in a reducing 4-12% NuPAGE gels stained
with SimplyB!ue SafeStain (Invitrogen Corp.). The more
clear Fab and Fe fraction were chosen and concentrated
using a Vivaspin 20 centrifugal concentrator (10-kDa
molecular weight cutoff; Sartorius Stedim Biotech).
Statistical Analysis.
Data are expressed as mean±SEM, with P<0.05 considered statistically significant. Differences among groups were
tested by one-way ANOVA. Tukey HD test was used as a
post hoc test to identify which group differences account for
the significant overall ANOVA. All calculations were carried
out using SPSS statistical package (vers 12.1; SPSS, Inc.,
Chicago, Ill.).
Throughout this document, various references are mentioned. All such references are incorporated herein by reference, including the references set forth in the following
list:
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All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication,
patent, or patent application was specifically and individually indicated to be incorporated by reference.
It will be understood that various details of the presently
disclosed subject matter can be changed without departing
from the scope of the subject matter disclosed herein.
Furthermore, the foregoing description is for the purpose of
illustration only, and not for the purpose of limitation.
What is claimed is:
1. A method of suppressing angiogenesis, comprising:
intravitreously administering to a subject in need of
treatment for a condition associated with angiogenesis
an isolated Fe fragment of an IgGl antibody, wherein
the administered Fe fragment decreases new blood
vessel formation.
2. The method of claim 1, and further comprising administering a drug selected from the group consisting of: bevacizumab, ranibizumab, trastuzumab, sorafenib (Nexavar),
sunitinib (Sutent), pazopanib (Votrient), everolimus (Afinitor).
3. The method of claim 1, wherein the antibody 1s
monoclonal.
4. The method of claim 1, wherein the antibody 1s
humanized.
5. The method of claim 1, further comprising administering an additional therapeutic agent.
6. The method of claim 5, wherein the additional therapeutic agent is an angiogenesis-inhibiting compound.
7. The method of claim 5, wherein the additional therapeutic agent is an anticancer compound.
8. The method of claim 1, wherein the subject is a human.
9. The method of claim 1, wherein the IgGl antibody is
not selected from the group consisting of bevacizumab,
trastuzumab, ado-trastuzumab emtansine, adalimumab, golimumab, efalizumab, canakinumab, pertuzumab, and intravenous immunoglobulin; or is selected from the group
consisting oftocilizumab, atilizumab, ofatumumab, alemtuzumab, palivizumab, motavizumab, raxibacumab, belimumab, omalizumab, ipilmumab, daclizumab, ustekinumab,
alefacept, elotuzumab, ACE-011, ACE-031, MGAWNl,
NCTOl 736683, MNRP1685A, IMC-A12, IMC 11218,
FG-3019, MT203, necitumumab, immunex, hLLl,
IMGN388, AMG 479, AIN457, CD4-IgG, 1695, BIIB023,
AIN457, IMC-11218, MEDI4893, nimotuzumab, mepolizumab, TRC105, solanezumab, and ficlatuzumab.
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